Conditional approval extended through December 2026 for the treatment of CID in dogsCID confirmatory effectiveness trial expected to conclude in...
Conditional approval extended through December 2026 for the treatment of CID in dogsCID confirmatory effectiveness trial expected to conclude in...
Conditional approval extended through December 2026 for the treatment of CID in dogsCID confirmatory effectiveness trial expected to conclude in...
SAN DIEGO, CA / ACCESS Newswire / December 10, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"),...
SAN DIEGO, CA / ACCESS Newswire / December 10, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"),...
The new partnership expands nutrition counseling and DSME services for Molina Commercial and Medicare members statewide to support long-term health...
Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant...
Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant...
U.S. Losartan market totals $245M annually with 71M prescriptions COMMACK, NY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC....
U.S. Losartan market totals $245M annually with 71M prescriptions COMMACK, NY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC....
DELRAY BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq:...
DELRAY BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq:...
Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical...
Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical...
Strategic Co-Development Partnership Expands Relationship between Bon Secours Mercy Health and Atalan to Unify Workforce and Patient Experience AnalyticsPHILADELPHIA, Dec....
Strategic Co-Development Partnership Expands Relationship between Bon Secours Mercy Health and Atalan to Unify Workforce and Patient Experience AnalyticsPHILADELPHIA, Dec....
VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000...
VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000...
WINNIPEG, Manitoba, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces...
WINNIPEG, Manitoba, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces...